- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03961321
Stereotactic MR-guided Adaptive Radiation Therapy for Localized Prostate Cancer (SMART)
SMART (Stereotactic MR-guided Adaptive Radiation Therapy) for Localized Prostate Cancer; a Phase II Study
Rationale: This prospective study investigates the outcomes of daily online stereotactic MR-guided adaptive radiation therapy (SMART) in patients with localized prostate cancer (cT1c-T3bN0M0). Visualization of the prostate, rectum and bladder prior to and during radiation delivery can be used to deliver "gated" treatment (beam-on only when the prostate is in the predetermined position) using small uncertainty margins. The novel MRIdian treatment delivery system (ViewRay, USA), which will be used for this study, allows for the immediate generation of an optimal radiotherapy plan based on the current anatomy of the prostate and surrounding normal organs prior to each fraction. These major advances will (i.e. dosimetrically) allow for an optimisation of normal tissue radiation doses, which should theoretically decrease toxicity to surrounding organs such as the rectum or bladder. Another advantage of this approach is that online MR-based prostate imaging does not rely on implanted gold markers, avoiding an invasive procedure to insert such markers. If proven feasible, this approach could set a new standard of care for patients with localized prostate cancer.
The main goal of this phase II study of SMART for prostate cancer is to evaluate the early and early-delayed toxicity, i.e. within the first year after treatment. An established 5-fraction hypofractionated radiation scheme will be used in this trial.
Main outcome parameters will include gastro-intestinal, genitourinary and sexual symptoms, which will be monitored at fixed time points using CTCAE criteria. In addition, patient-reported outcomes will be evaluated using EORTC-QOL questionnaires.
Objective: To investigate the early and early-delayed toxicity profile of SMART in patients with localized prostate cancer.
Study design:phase II observational study Study population: 100 consecutive patients with localized prostate cancer (cT1c-T3bN0M0).
Study intervention: Study patients will be treated with an online MR-guided hypofractionated course of radiotherapy in 5 fractions of 7.25 Gy per fraction delivered on the prostate with a simultaneous integrated sparing of the urethra with a dose of 32.5 Gy in 5 fractions Main study parameters: Early and early-delayed toxicity (CTCAE v. 4.0); (IPSS) and Qol C30 PR25. Secondary endpoint will be the offline evaluation of the dosimetric benefit of SMART by comparing cumulative doses to organs at risk.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: This prospective study investigates the outcomes of daily online stereotactic MR-guided adaptive radiation therapy (SMART) in patients with localized prostate cancer (cT1c-T3bN0M0). Visualization of the prostate, rectum and bladder prior to and during radiation delivery can be used to deliver "gated" treatment (beam-on only when the prostate is in the predetermined position) using small uncertainty margins. The novel MRIdian treatment delivery system (ViewRay, USA), which will be used for this study, allows for the immediate generation of an optimal radiotherapy plan based on the current anatomy of the prostate and surrounding normal organs prior to each fraction. These major advances will (i.e. dosimetrically) allow for an optimisation of normal tissue radiation doses, which should theoretically decrease toxicity to surrounding organs such as the rectum or bladder. Another advantage of this approach is that online MR-based prostate imaging does not rely on implanted gold markers, avoiding an invasive procedure to insert such markers. If proven feasible, this approach could set a new standard of care for patients with localized prostate cancer.
The main goal of this phase II study of SMART for prostate cancer is to evaluate the early and early-delayed toxicity, i.e. within the first year after treatment. An established 5-fraction hypofractionated radiation scheme will be used in this trial. At VUmc, experience with this scheme has been obtained as a result of participation in a recently concluded multicenter randomized phase II trial [METc NL4181402912; 20012/398]. Main outcome parameters will include gastro-intestinal- (GI), genitourinary- (GU) and sexual symptoms, which will be monitored at fixed time points using CTCAE criteria. In addition, patient-reported outcomes will be evaluated using EORTC-QOL questionnaires.
Objective: To investigate the early and early-delayed toxicity profile of SMART in patients with localized prostate cancer.
Study design: A phase II observational study Study population: 100 consecutive patients with localized prostate cancer (cT1c-T3bN0M0).
Study intervention: Study patients will be treated with an online MR-guided hypofractionated course of radiotherapy in 5 fractions of 7.25 Gy per fraction delivered on the prostate with a simultaneous integrated sparing (SIS) of the urethra with a dose of 32.5 Gy in 5 fractions (6.5 Gy per fraction). This stereotactic radiation scheme was also used in [METc NL4181402912; 20012/398].
Main study parameters: Early and early-delayed toxicity (CTCAE v. 4.0); prostate specific symptom score (IPSS) and Qol (EORTC-QoL C30 & QLQ Prostate Cancer module (QLQ-PR25)). Secondary endpoint will be the offline evaluation of the dosimetric benefit of SMART by comparing cumulative doses to organs at risk.
Nature, extent of the burden and risks associated with participation, benefit and group relatedness: This novel SMART approach could set a new standard of care for patients with localized prostate cancer by limiting radiation doses to surrounding normal organs and thereby potentially radiation-induced toxicity. Also, implantation of gold markers would become unnecessary using MR-guided "gated" radiotherapy. Disadvantages for patients include the need to be positioned within the MRI bore during radiation delivery, and a prolonged time per treatment fraction (estimated at 30 minutes per fraction), which has to be weighed against the use of a total of only five fractions. As the radiation fractionation scheme that is used in this study has been evaluated in prior trials, no further patient-related risks are anticipated.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands, 1081HV
- VU University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Age of 18 years or older
- WHO performance score 0-2
- Biopsy proven adenocarcinoma of the prostate
- Gleason ≥ 6
- Prostate volume ≤ 90 cc on TRUS
- T-stage: cT1c-T3b (on MRI and/or endorectal ultrasound)
- All patients should be able to undergo MRI scans
- No evidence of lymph node or distant metastases on radiological staging
- The multidisciplinary team advised external beam radiotherapy treatment
- IPSS (International Prostate Symptoms Score) ≤19
- Previous TURP is allowed provided there is at least 8 weeks interval with radiotherapy
- The administration of concomitant hormonal therapy is allowed
- Ability to provide written informed consent.
Exclusion Criteria:
- Previous irradiation in the pelvic region
Contra-indications for MRI
- As no safety data for 0.35 Tesla MRI scanners are available on electronic devices such as pacemakers or implanted defibrillators, deep brain stimulators, cochlear implants, this constitutes an absolute contraindication for this study, even for devices that have been considered safe for MRI scans with higher magnetic field strengths.
- Patients who have a metallic foreign body in their eye, or who have an aneurysm clip in their brain, cannot have an MRI scan since the magnetic field may dislodge the metal
- Patients with severe claustrophobia may not be able to tolerate an MRI scan
- Patients with a hip prosthesis will not be eligible for the MRI scan
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Early gastrointestinal toxicity
Time Frame: determined at 3 months
|
Common Terminology Criteria for Adverse Events (CTCAE v4.0)
|
determined at 3 months
|
Late gastrointestinal toxicity
Time Frame: determined at 12 months
|
Common Terminology Criteria for Adverse Events (CTCAE v4.0)
|
determined at 12 months
|
Early genitourinary toxicity
Time Frame: determined at 3 months
|
Common Terminology Criteria for Adverse Events (CTCAE v4.0)
|
determined at 3 months
|
Late genitourinary toxicity
Time Frame: determined at 12 months
|
Common Terminology Criteria for Adverse Events (CTCAE v4.0)
|
determined at 12 months
|
Early quality of life (QoL)
Time Frame: determined at 3 months
|
EORTC QoL core questionnaire (QLQ-C30)
|
determined at 3 months
|
Early prostate specific quality of life (QoL)
Time Frame: determined at 3 months
|
EORTC QLQ-PR25
|
determined at 3 months
|
Late quality of life (QoL)
Time Frame: determined at 12 months
|
EORTC QoL core questionnaire (QLQ-C30)
|
determined at 12 months
|
Late prostate specific quality of life (QoL)
Time Frame: determined at 12 months
|
EORTC QLQ-PR25
|
determined at 12 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Anna Bruynzeel, MD, PhD, Amsterdam UMC, location VUmc
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL5728902916
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Prostatic Neoplasms
-
Australian and New Zealand Urogenital and Prostate...Peter MacCallum Cancer Centre, AustraliaRecruitingCastration Resistant Prostatic CancerAustralia
-
British Columbia Cancer AgencySanofi; Ozmosis Research Inc.UnknownMetastatic Castration-Resistant Prostatic CancerCanada, Australia
-
Technische Universität DresdenRecruitingOligometastatic Disease | Prostatic Cancer, Castration-ResistantGermany
-
Yinghao SunNot yet recruitingCastration-Resistant Prostatic Cancer
-
Institut Claudius RegaudWithdrawnProstatic Cancer, Castration-ResistantFrance
-
Janssen Research & Development, LLCCompletedCastration-Resistant Prostatic NeoplasmsCanada, Belgium, United States, Spain, Netherlands, Italy, Russian Federation
-
Universität des SaarlandesRecruitingProstate Cancer Metastatic | Advanced Prostate Carcinoma | Castration Resistant Prostatic CancerGermany
-
University Hospital, GrenobleTerminatedCastration-resistant Prostate CancerFrance
-
Rio de Janeiro State UniversityCompletedProstatic Cancer | Prostatic NeoplasmBrazil
-
Michael Graham PhD, MDUniversity of Iowa; Holden Comprehensive Cancer CenterActive, not recruitingProstate Cancer | Prostatic Neoplasms, Castration-Resistant | Prostatic Neoplasm | Prostatic Cancer Recurrent | Prostatic Cancer MetastaticUnited States
Clinical Trials on stereotactic mr guided adaptive radiotherapy
-
Washington University School of MedicineCompletedOligometastases of the SpineUnited States
-
Washington University School of MedicineVarian Medical SystemsCompletedAny Solid Malignancies of Any Tissue Origin (Except for Small Cell Lung Cancer) Involving the Upper Abdomen and ThoraxUnited States
-
M.D. Anderson Cancer CenterRecruiting
-
Washington University School of MedicineVarian Medical SystemsRecruitingNon-small Cell Lung Cancer | Early Stage Non-small Cell Lung CancerUnited States
-
Centre Georges Francois LeclercActive, not recruiting
-
Baptist Health South FloridaWithdrawnLung Cancer | Lung TumorUnited States
-
Henry Ford Health SystemNot yet recruitingCarcinoma, Non-Small-Cell Lung
-
Odense University HospitalNovo Nordisk A/S; AgeCare Academy of Geriatric Cancer ResearchCompleted
-
National Taiwan University HospitalUnknownMetastasis of Malignant Neoplasm to Lymph NodeTaiwan
-
University Hospital, EssenRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Adaptive Radiotherapy | OptimizationGermany